Association of neutrophil-to-lymphocyte ratio with antipsychotic administration in schizophrenia: A longitudinal study

Association of neutrophil-to-lymphocyte ratio with antipsychotic administration in schizophrenia: A longitudinal study

Background: Studies have hypothesized the role of the immune–inflammatory process behind the pathophysiology of psychiatric disorders like schizophrenia. Antipsychotic medication has been shown to suppress inflammatory response via complex mechanisms alleviating psychiatric symptoms. Aim: To assess...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rajnish Raj, Shabir Ahmad Dar, Zaid Ahmad Wani, Vaibhav Kumar Khare, Inaamul Haq
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-01-01
Series:	Industrial Psychiatry Journal
Subjects:	anti-inflammatory antipsychotic neutrophil ratio nlr schizophrenia
Online Access:	https://journals.lww.com/10.4103/ipj.ipj_6_25
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neutrophil/lymphocyte ratio is increased in the acute phase of schizophrenia and regardless the use and types of antipsychotic drugs
by: Yali Zheng, et al.
Published: (2024-12-01)

The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital
by: Isnenia Isnenia
Published: (2022-03-01)

The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China
by: Huaning Wang, et al.
Published: (2025-07-01)

Correction: The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

The Prevalence of Tardive Dyskinesia In Patients With Schizophrenia Treated With Antipsychotics In Malaysia
by: Nedunjelian A, et al.
Published: (2025-03-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
by: S. A. Galkin, et al.
Published: (2024-04-01)

Guideline for the use of therapeutic drug monitoring of antipsychotics to individualize the selection of therapy in the treatment of exacerbation of schizophrenia
by: S. S. Potanin, et al.
Published: (2023-12-01)

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia
by: Kulaksizoglu B, et al.
Published: (2016-08-01)

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Haloperidol versus second-generation antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials
by: Daniel Prates Baldez, et al.
Published: (2025-05-01)

The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study
by: Tobechukwu C. Iyidobi, et al.
Published: (2025-07-01)

Dopamine receptor DRD1 expression (mRNA, protein level) in peripheral blood lymphocytes and prognosis of antipsychotic therapy
by: A. M. Zabotina, et al.
Published: (2022-11-01)

QT interval prolongation from antipsychotics in schizophrenia and acute psychosis - A prospective study
by: Anirban Saha, et al.
Published: (2025-05-01)

The use of antipsychotics in the treatment of catatonia: a systematic review
by: Maximilien Redon, et al.
Published: (2025-01-01)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
by: de Bartolomeis A, et al.
Published: (2016-01-01)

Influence of Polymorphisms in Gene SATB2 on Antipsychotics Response in Chinese Han Population
by: Du X, et al.
Published: (2025-07-01)

Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al.

Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs
by: Shuzhan Gao, et al.
Published: (2025-03-01)

Pharmacologic Advancement in Schizophrenia
by: Hafiza Tuseef Sayyar, et al.
Published: (2021-03-01)

Can neutrophil/lymphocyte ratio be a predictor for bone metastases of solid tumors?
by: Billur Caliskan, et al.
Published: (2016-07-01)

Elevated Neutrophil‐to‐Lymphocyte Ratio Correlates With Liver Metastases and Poor Immunotherapy Response in Stage IV Melanoma
by: Yannick Foerster, et al.
Published: (2025-02-01)

INTERLEUKIN-18 LEVELS IN SCHIZOPHRENIA PATIENTS RECEIVING ANTI-PSYCHOTIC THERAPY AT THE PSYCHIATRIC POLYCLINIC OF SITI RAHMAH ISLAMIC HOSPITAL
by: Dita Hasni, et al.
Published: (2025-01-01)

Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2020-10-01)

Modern approaches to the therapy of schizophrenia with atypical neuroleptics (based on clinical observations)
by: D. D. Samoylov, et al.
Published: (2024-12-01)

IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
by: Paula M. Moran, et al.
Published: (2025-06-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Influence of antipsychotic drugs on microglia-mediated neuroinflammation in schizophrenia: perspectives in an astrocyte–microglia co-culture model
by: Timo Jendrik Faustmann, et al.
Published: (2025-03-01)

Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients
by: Dieter Naber, et al.
Published: (2009-10-01)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
by: Junwen Zhou, et al.
Published: (2019-01-01)

Comparative analysis of antipsychotic drug consumption for inpatient schizophrenia treatment: a retrospective study with 5-year follow-up
by: L. B. Vaskova, et al.
Published: (2020-11-01)

New approaches to pharmacogenetics of drug-induced hyperprolactinemia in patients with schizophrenia
by: S. A. Ivanova
Published: (2019-12-01)

Polymorphic variant of <i>NQO1</i> rs1800566 and antipsychotic-induced metabolic disorders in patients with schizophrenia
by: V. V. Tiguntsev, et al.
Published: (2025-07-01)

Sexual dysfunction and other prolactin-related side effects of antipsychotic drugs in schizophrenia: Protocol for a systematic review with single-arm, pairwise, and network meta-analyses of randomized controlled trials and non-randomized studies [version 2; peer review: 2 approved, 1 approved with reservations]
by: Wulf Peter Hansen, et al.
Published: (2025-02-01)

Enhanced treatment outcomes for schizophrenia through combined long-acting injectable antipsychotic medications and home visits: retrospective cohort study
by: Hiroyuki Harada, et al.
Published: (2025-09-01)

DOPAMINE RECEPTOR D2 (DRD2) IN PERIPHERAL BLOOD LYMPHOCYTES AS BIOMARKER OF RESPONSE TO ANTIPSYCHOTIC MEDICATION
by: M. N. Grunina, et al.
Published: (2020-05-01)